Winner of the IQ Innovation Award Central Germany 2019

We were recently awarded the main prize of the 15th IQ Innovation Award Central Germany for the development of a new anti-tuberculosis agent, which represents a new compound class against multi-resistant forms of the tuberculosis pathogen. The compound is being developed into a drug by our team together with partners at the University Hospital of Munich and the company HAPILA GmbH Gera.